Stifel Nicolaus reaffirmed their buy rating on shares of Halyard Health, Inc. (NYSE:HYH) in a research note published on Thursday morning. Stifel Nicolaus currently has a $45.00 price target on the medical instruments supplier’s stock.

Several other equities analysts have also recently issued reports on HYH. TheStreet raised Halyard Health from a c rating to a b rating in a research note on Thursday, June 22nd. BidaskClub raised Halyard Health from a hold rating to a buy rating in a research note on Wednesday, June 28th. Zacks Investment Research raised Halyard Health from a hold rating to a buy rating and set a $44.00 target price on the stock in a research note on Wednesday, July 12th. Stephens raised Halyard Health from an equal weight rating to an overweight rating in a research note on Thursday, August 3rd. Finally, Deutsche Bank AG boosted their target price on Halyard Health from $35.00 to $42.00 and gave the company a buy rating in a research note on Thursday, August 3rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Halyard Health currently has a consensus rating of Buy and an average target price of $42.25.

Shares of Halyard Health (NYSE HYH) opened at 46.07 on Thursday. The stock’s 50 day moving average is $43.72 and its 200 day moving average is $39.69. Halyard Health has a 12 month low of $31.59 and a 12 month high of $46.36. The firm has a market cap of $2.15 billion, a P/E ratio of 44.30 and a beta of 1.76.

Halyard Health (NYSE:HYH) last posted its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.14. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The firm had revenue of $399.20 million for the quarter, compared to analysts’ expectations of $399.16 million. During the same period in the previous year, the firm earned $0.45 earnings per share. The business’s revenue was down .2% compared to the same quarter last year. Equities research analysts expect that Halyard Health will post $1.97 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Halyard Health, Inc. (HYH) Earns “Buy” Rating from Stifel Nicolaus” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/25/halyard-health-inc-hyh-earns-buy-rating-from-stifel-nicolaus.html.

A number of hedge funds have recently modified their holdings of HYH. Meadow Creek Investment Management LLC grew its stake in Halyard Health by 1.1% in the first quarter. Meadow Creek Investment Management LLC now owns 2,660 shares of the medical instruments supplier’s stock worth $101,000 after purchasing an additional 28 shares during the period. Riverhead Capital Management LLC grew its stake in Halyard Health by 88.1% in the second quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock worth $126,000 after purchasing an additional 1,497 shares during the period. Victory Capital Management Inc. purchased a new stake in Halyard Health in the first quarter worth $153,000. LS Investment Advisors LLC grew its stake in Halyard Health by 16.1% in the second quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 556 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Halyard Health by 102.5% in the first quarter. Tower Research Capital LLC TRC now owns 4,836 shares of the medical instruments supplier’s stock worth $184,000 after purchasing an additional 2,448 shares during the period. 91.02% of the stock is currently owned by institutional investors.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.